Evidence map›Paper›PMID 40175553›Full record

ArticleNature2025

Psilocybin's lasting action requires pyramidal cell types and 5-HT

Ling-Xiao Shao, Clara Liao, Pasha A Davoudian, Neil K Savalia, Quan Jiang, Cassandra Wojtasiewicz, Diran Tan, Jack D Nothnagel, Rong-Jian Liu, Samuel C Woodburn and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Review
  2. Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Mechanistic Basis for 5-HTNature communications · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Psilocybin restores behavior and 5-HTCell reports. Medicine · 2026
    Article
  12. Article
  13. Article
  14. Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  15. Article
  16. Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin.bioRxiv : the preprint server for biology · 2026
    Article
  17. The working lives of neuronal 5-HTRSC chemical biology · 2026
    Review
  18. Article
  19. Review
  20. Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ling-Xiao Shao *Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.ORCID 0009-0006-9503-1230
Clara Liao *Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Pasha A DavoudianMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-5096-7610
Neil K SavaliaMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Quan JiangMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Cassandra WojtasiewiczMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Diran TanMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Jack D NothnagelMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Rong-Jian LiuDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Samuel C WoodburnMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Olesia M BilashMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Hail KimGraduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea.ORCID 0000-0002-6652-1349
Alicia CheDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-7530-8531
Alex C KwanMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA. alex.kwan@cornell.edu.ORCID 0000-0003-2169-1667

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Interdepartmental Neuroscience Program (INP)T32NS041228 · NINDS · YALE UNIVERSITY · PI Charles A Greer, Marina R Picciotto · 2001 to 2026
$12.0M
TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Cellular basis of psilocybin actions in frontal cortexR01MH128217 · NIMH · CORNELL UNIVERSITY · PI CHUN-HAY ALEX KWAN · 2022 to 2026
$2.9M
A Dendritic Substrate for Fast-Acting Antidepressant ActionR01MH121848 · NIMH · YALE UNIVERSITY · PI KWAN, CHUN-HAY ALEX · 2020 to 2024
$2.6M
Deep and Fast Imaging Using Adaptive Excitation SourcesU01NS128660 · NINDS · CORNELL UNIVERSITY · PI XU, CHRIS · 2022 to 2025
$2.4M
Role of cortical GABAergic interneurons in psychedelic drug actionR01MH137047 · NIMH · CORNELL UNIVERSITY · PI CHUN-HAY ALEX KWAN · 2024 to 2026
$1.9M
Neural Mechanisms Linking Sensory Perception and Social BehaviorR01NS133434 · NINDS · YALE UNIVERSITY · PI Alicia Yue Che · 2023 to 2026
$1.6M
Effects of Early-life Cannabinoid Exposure on Prefrontal Circuitry and Cognitive Behavior across DevelopmentR01DA059378 · NIDA · YALE UNIVERSITY · PI Alicia Yue Che · 2024 to 2026
$1.5M
Maturation of Somatosensory Circuits for Social BehaviorsR00NS114166 · NINDS · YALE UNIVERSITY · PI CHE, ALICIA YUE · 2022 to 2024
$740k
Zeiss LSM710 Confocal Microscope for Shared Imaging FacilityS10RR025502 · NCRR · CORNELL UNIVERSITY · PI WILLIAMS, REBECCA M · 2009 to 2009
$500k
Acquisition of an automated phase and fluorescence microscope for Cornell BRC Imaging FacilityS10OD032251 · OD · CORNELL UNIVERSITY · PI WILLIAMS, REBECCA M · 2022 to 2022
$229k
NCRR NIH HHS S10 RR025502NIAID NIH HHS T32 AI007517NIDA NIH HHS F30 DA059437NIDA NIH HHS R01 DA059378NIGMS NIH HHS T32 GM007205NIH HHS S10 OD032251NIMH NIH HHS F30 MH129085NIMH NIH HHS R01 MH121848NIMH NIH HHS R01 MH128217NIMH NIH HHS R01 MH137047NINDS NIH HHS R00 NS114166NINDS NIH HHS R01 NS133434NINDS NIH HHS T32 NS041228NINDS NIH HHS U01 NS128660
6 · The paper itself

Abstract

Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses

Indexed as

HallucinogensPsilocybinPyramidal CellsReceptor, Serotonin, 5-HT2AAction PotentialsAnimalsCalciumDendritic SpinesFemaleFrontal LobeMaleMiceMice, Inbred C57BLNeuronal PlasticityCalciumHallucinogensPsilocybinReceptor, Serotonin, 5-HT2A

Identifiers

PMID40175553
PMCPMC12188471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.